Archive for the ‘nature publishing group’ Category
Last month, researchers published a paper whose conclusions suggested that looking at Arctic sea ice in the autumn offers clues to winter temperatures in Europe.
The letter appeared — briefly, as this post will demonstrate — in Nature Geoscience. The letter, titled “High predictability of the winter Euro–Atlantic climate from cryospheric variability,” was written by Javier Garcia-Serrano and Claude Frankignoul, of the Université Pierre et Marie Curie. The journal published the letter on March 23 and retracted it on April 14.
Here’s the abstract, which can still be found online:
Brutal honesty: Author takes to PubPeer to announce retraction — and tells us she’ll lose PhD, professorship
The comments suggested that the figures in the paper had problems. Some bands seemed to be duplicated, and one of the images looked very much like that of another paper.
Last year, we reported on a Nature correction of a paper for what a McGill University committee had earlier called “intentionally contrived and falsified” figures. It turns out that the correction — like the original paper — left some Nature readers puzzled, so the journal has run a correction of the correction: Read the rest of this entry »
It’s not unusual to hear authors bemoan the fact that a new paper doesn’t cite their work that set the stage for a scientific advance. “The journal limited me to [a seemingly abitrary number of] references,” authors sometimes shrug, with or without apology. This week, however, we found a case of that which seems to have been resolved to everyone’s satisfaction.
The authors of a September 2013 article in Nature Communications have issued a correction for the piece, which failed to cite the source of a key step in their experiment.
The article, “Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction,” came from the lab of William “Clay” Bracken, a biochemist at Weill Cornell Medical College. According to the abstract: Read the rest of this entry »
Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of one researcher to note his Novartis affiliation. The company has apologized.
Here’s one retraction, from Diabetes Care, for “The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients With Type 2 Diabetes: The Shiga Microalbuminuria Reduction Trial (SMART):”
“I am deeply saddened and disturbed:” Co-author of retracted Nature paper reveals how problems came to light
On Wednesday, we reported on a Nature retraction of a paper whose corresponding author had also had a Cell paper retracted, and had been found to have committed a “violation of academic integrity” by Utrecht University. Today, we present the back story of how those retractions came to be, from another co-author of both papers, Ben Scheres, of Wageningen University: Read the rest of this entry »
A 2013 paper in Nature that was among those whose first or last author had committed a “violation of academic integrity,” according to Utrecht University, has been retracted.
The American Journal of Gastroenterology has retracted a 2011 article on colon cancer by a group of Cleveland Clinic researchers after finding “evidence” of plagiarism in the text.
The article, a review, was titled “Molecular Pathways Underlying IBD-Associated Colorectal Neoplasia: Therapeutic Implications,” and has been cited 16 times, according to Thomson Scientific’s Web of Knowledge.
An international team of researchers from the NIH, Harvard, the University of Michigan, and two Chinese universities — Fourth Military Medical University and China Medical University — has retracted their 2012 paper in Nature after they — and a number of other groups — were unable to reproduce the key results.
The original abstract for “The NAD-dependent deacetylase SIRT2 is required for programmed necrosis” said that the findings
implicate SIRT2 as an important regulator of programmed necrosis and indicate that inhibitors of this deacetylase may constitute a novel approach to protect against necrotic injuries, including ischaemic stroke and myocardial infarction.